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IntrOductIOn
Desmoid Tumours (DT), also known as aggressive fibromatosis, is 
part of a group of fibroproliferative diseases. They result from the 
proliferation of monoclonal cells of fibroblastic origin. They don’t 
metastasize, hence they are not considered malignant. They can 
however be aggressive due to their infiltrative nature, possible 
multifocality and tendency to recur [1-5].
These tumours are rare, with an estimated incidence of 2-4 per 
million per year [4]. They are mostly sporadic but between 7-16% 
are associated with Familial Adenomatous Polyposis (FAP), as 
part of Gardner’s syndrome [1,6,7]. DT are an important cause of 
morbidity and mortality in patients with FAP, occurring in 12-15% 
of these patients [1,8]. 
FAP is related to mutations on Adenomatous Polyposis Coli gene 
(APC), which is a tumour suppressor gene. APC protein degrades 
β-catenin, which is implicated in cell proliferation regulation. 
The truncated APC protein is unable to perform its function 
appropriately [9]. The mutation site on the APC gene is associated 
to FAP phenotype, including DT development. The more distal the 
mutation (closer to 3’ end), the higher the risk of the patient being 
affected by DT [1,9,10].
Other factors involved in the development of DT are previous 
abdominal surgery and family history of DT [11,12]. Female sex 
has been reported as a risk factor but findings are not consistent 
[11,12].
Despite the possibility of DT arising in any location, DT related to 
FAP are mostly on the abdominal region: intra-abdominal, on the 
abdominal wall and “transabdominal” [1,7].
 
Some of them take a benign course, with indolent evolution, 
stabilization of growth or even remission. Others show an 
aggressive behaviour with rapid growth and mass effect on 
surrounding structures, particularly in case of intra-abdominal 
DT. Possible complications of intra-abdominal DT are intestinal 
obstruction, ischemia, haemorrhage and perforation or ureteric 
obstruction [1,4,8].
When DT develops in FAP patients, they are the second most 
common cause of mortality [13]. DT are challenging because of 
their unpredictable natural course, associated complications and 
difficult treatment. The aim of the present study was to review the 
occurrence, management and follow-up of DT on FAP patients 
treated conse cutively at a tertiary center.
MAterIAls And MethOds
This was a retrospective review of a cohort of patients with FAP, 
treated consecutively at a Digestive Surgery Unit of a single tertiary 
referral center, between 1993 and 2014, who developed DT. 
Patients underwent clinical evaluation every 6 months.
The study was approved by the general surgery scientific 
commission and institutional review board. We consulted patients’ 
clinical records and gathered data with full anonymity.
Data collection included the following variables: demographic data 
(age, sex), genotype (APC mutation), FAP phenotype, data on FAP 
related surgery (age, type of surgery), DT diagnosis, location, size 
and number, DT treatment, patient’s status and follow-up data. 
Considering the location of tumours, if a patient had at least one 
tumour with an intra-abdominal component, we classified them as 
intra-abdominal.
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ABstrAct
Introduction: Desmoid Tumours (DT) are benign tumours with 
an estimated incidence of 2-4 per million per year. Between 
7-16% of them are associated with Familial Adenomatous 
Polyposis (FAP) and are mostly parietal or intra-abdominal. 
They are a challenge in relation to their unpredictable natural 
course, associated complications and difficult treatment.
Aim:  The aim of the present study was to review the occurrence, 
management and follow-up of DT on FAP patients treated 
consecutively at a tertiary care center.
Materials and Methods: A retrospective review of clinical 
data from patients treated consecutively between 1993 and 
2014. Patients’ data was gathered from clinical records. Data 
collection included the following variables: demographic data, 
genotype, FAP phenotype, data on FAP related surgery, DT 
diagnosis, location, size and number, DT treatment, patients’ 
status and follow-up data. 
results: The study population consisted of 17 patients from 9 
families; with a mean age of 41 years, mostly women (59%) and 
most with a mutation either on codon 232 or 554. Most tumours 
had an intra-abdominal component (59%) with a mean size of 
5cm. Fifteen patients were first treated with pharmacotherapy 
(Non-steroidal Anti-inflammatory Drugs (NSAIDs) and 
Tamoxifen). Five patients (29%) underwent surgery, 4 of them 
for complications of intra-abdominal tumours and 1 patient for 
abdominal wall tumours. Two patients underwent chemotherapy 
in relation to aggressive intra-abdominal disease. The mean 
follow-up time since diagnosis of DT was 123 months. Overall, 2 
patients had remission, 11 patients had regression or stabilized 
disease, and 2 patients had progression. One patient died due 
to surgical complications.
conclusion: Diagnosis of DT is based on clinical symptoms, 
without the need for screening, although imaging plays an 
important role once diagnosis is suspected. The treatment 
approach is conservative on most patients, leaving surgery for 
DT related complications. The follow-up of patients with DT is 
also based on clinical symptoms.
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Patients were also staged according to Church et al., which is a 
proposed staging system for intra-abdominal DT [8]. This staging 
system allows stratification of this set of patients by disease 
severity. In case of multiple DT, the clinically more relevant lesion 
was used to classify the disease.
results
Our population consisted of 17 patients, belonging to 9 families, 
most being women (59%) with mean age of 41years. Ten patients 
belonging to 2 families had mutations on codon 232 and 554 (5 
patients each). Five patients from different families had mutations 
on codons 554, 625, 1009, 1309 and 1465. The APC mutation 
could not be determined on 2 unrelated patients. These patients 
were also tested for MUTYH gene mutations and microsatellite 
instability with negative results. Patients with mutation on codon 
232 (all from same family) had attenuated FAP. All other patients 
had classic FAP.
[Table/Fig-1] gives an overview of our population of FAP patients 
with desmoids. All patients underwent prophylactic colorectal 
surgery before diagnosis of DT. The FAP related surgery was a 
coloprotectomy with ileoanal pouch in 10 patients (59%) or a 
colectomy with ileorrectal anastomosis (41%) according to rectal 
presentation of the disease. The mean time between surgery and 
the first DT diagnosis was 60months (6-94months), with a mean 
age of 30 years at DT diagnosis.
The diagnosis was first suspected clinically in 13 patients (76%) 
on palpation of an abdominal mass and then confirmed and 
characterized by Computed Tomography (CT) scan. Three patients 
presented with ileoanal pouch dysfunction and were investigated 
with CT scan. One patient had diagnosis during surgery for 
Gastrointestinal Haemorrhage (GIH).
Ten patients (59%) had intra-abdominal tumours with a mean size 
of 5cm, while the rest were located on the abdominal wall (41%) 
with a mean size of 4.5cm. One patient developed 1 intra-thoracic 
tumour diagnosed during follow-up. [Table/Fig-2] presents more 
information regarding intra-abdominal tumours.
Fifteen patients were first treated with pharmacotherapy [Table/
Fig-1,3]. Pharmacotherapy consisted of Non-steroidal Anti-
inflammatory Drugs (NSAIDs) as first line of treatment– sulindac 
until it was discontinued in Portugal in 2008, and then celecoxib. 
Tamoxifen was the second line of treatment, mostly associated 
with NSAIDs, usually with progressive dosing as required, up to 
120mg/day. Two patients didn’t tolerate NSAIDs; one because 
of profuse diarrhea, the other had ileoanal pouch bleeding. The 
former stayed on tamoxifen alone, the latter had no therapy since 
he remained asymptomatic and the tumour remained stable. Ten 
patients (59%) underwent pharmacotherapy as the sole treatment 
during follow-up time. The remaining patients underwent either 
surgery or chemotherapy, except one patient who had a recent 
clinically detected abdominal wall DT. He had a pericentimetric 
tumour and was asymptomatic. He was left untreated at the 
time of diagnosis, in order to assess the presence of other DT at 
different locations by CT scan.
Five patients (29%) have been submitted to DT related surgery. 
Despite different initial staging [Table/Fig-3], the indication for 
surgery was related to complications on 4 patients which had 
intra-abdominal DT – they all evolved to stage IV disease:
- One patient was initial stage III - slow growing of DT – and 
started NSAIDs at diagnosis. On the second year of DT follow-
up, the patient had a small bowel perforation associated with 
bowel erosion by the tumour. An enterectomy was performed 
and the resection was considered R2. The patient died of 
septic complications in the late post-operative period, without 
anastomotic leakage. 
- One patient started NSAIDs and tamoxifen once diagnosed with 
intra-abdominal DT. Nine months later, the patient progressed 
from stage I to stage IV and underwent emergent surgery for 
GIH– R0 resection.
- One patient was diagnosed at the time of emergent surgery. The 
patient underwent a R2 resection and needed chemotherapy.
- The fourth patient who underwent surgery for intra-abdominal DT 
n* Sex FaP Surgery age  (years) Dt location Dt treatment Months of 
follow-up
outcome
FaP surgery Dt diagnosis
1 F IRA† 37 38 AW§ NSAID’s / surgery 216 Progression 
2 F CPIP‡ 25 26 IA|| NSAID’s 216 Remission
3 F IRA 27 28 IA NSAID’s / tamoxifen 216 Stable
4 M CPIP 25 28 IA NSAID’s / tamoxifen 204 Stable
5 F CPIP 39 43 IA tamoxifen / surgery 141 Stable
6 M IRA 32 36 AW / IA surgery / chemo**/ NSAID’s 146 Stable
7 F IRA 29 29 AW NSAID’s 144 Stable
8 F IRA 54 54 IA NSAID’s/ surgery 36 Death
9 F CPIP 18 19 AW NSAID’s / tamoxifen 108 Regression
10 F CPIP 20 31 IA NSAID’S / tamoxifen / surgery 106 Remission
11 M CPIP 17 18 AW NSAID’s / tamoxifen 106 Progression
12 M IRA 18 19 AW NSAID’s 67 Stable
13 F CPIP 17 30 IA NSAID’s 72 Stable
14 M IRA 33 47 IA NSAID’s 252 Regression
15 F CPIP 22 22 AW / IA NSAID’s/ tamoxifen / chemo 30 Regression
16 M CPIP 18 19 AW NSAID’s 29 Stable
17 M CPIP 19 22 AW - 6 Stable
total n n Mean Mean n n Mean n
17 10  F
7  M
10  CPIP
7 IRA  
26 30 (19-54) 8 - IA
7 - AW
2 - AW / IA
15 - NSAID’s
 7  - tamoxifen
 5 – surgery
 2 - chemo
123 (6-252) 9 - stable
3 - regression
2 - remission
2 - progression
1 - death
[table/Fig-1]: Population overview: demographic, clinical, treatment and outcome data of FAP patients With DT.
*N- refers to number of patients †IRA – colectomy with ileorrectal anastomosis ‡CPIP – coloprotectomy with ileoanal pouch
§AW – abdominal wall  ||IA – intra-abdominal   **chemo – chemotherapy
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was also stage I at the time of diagnosis. He was given NSAIDs 
but they were not tolerated (profuse diarrhea). For 7 years this 
patient’s therapy consisted of tamoxifen with regression of DT. 
She then progressed to stage IV, presenting extensive portal 
venous gas in relation to small bowel and mesenteric venous 
erosion by DT – a complete resection was performed.
- Only one patient with abdominal wall DT had surgery [Table/
Fig-1], based on referred discomfort, having two DT resected 
with histologic free margins. Both DT recurred on this patient, 
who also developed an intra-abdominal and intra-thoracic DT. 
The patient is currently treated with NSAIDs and tamoxifen.
Both patients with histologically free margins had DT recurrence 
and started pharmacotherapy. One patient is in remission while 
the other remains stable.
Only 2 patients underwent chemotherapy in relation to aggressive 
intra-abdominal disease, with progressive symptoms, and no 
response to NSAIDs or tamoxifen. Both patients were stage IV at 
presentation. One patient was already described and underwent 
surgery as first treatment but the other patient had no indication to 
surgery based on aggressive disease with no chance of resection 
free of iatrogenic complications. Chemotherapy regimen consisted 
of doxorubicin and dacarbazine, on both patients. Both had 
regression of disease and they are asymptomatic.
The mean follow-up time since diagnosis of DT was 123 months. 
Information about current patient status is presented on [Table/
Fig-4].
dIscussIOn
Our population of 17 patients from a single institution is in line 
with DT prevalence on FAP patients. The largest series reported 
are from multi-institutional or national studies [11]. Nieuwenhuis et 
al., reported 78 patients from a national Dutch Polyposis Registry 
[14].
The most important risk factors for the development of DT are 
previous surgery, family history and the position of the mutation on 
the APC gene [1,9-12,16]. There is no current evidence associating 
the type of surgery and the occurrence of DT. All patients from 
our population have been submitted to prophylactic colectomy/
coloprotectomy before the diagnosis of DT.
Ten of our patients (59%) belong to 2 families which is consistent 
with what is called family clustering [11,15,16]. Studies showed 
that tumours tended to cluster in susceptible individuals with a 
strong family history of DT, irrespective of the germline APC 
mutation [15]. 
It is known that the phenotype of FAP is related to the position of 
the APC gene mutation [9]. Regarding extra colonic manifestations 
of FAP, some patients are affected more severely than others, 
depending on the site of the mutation [10]. There is some evidence 
that mutations on the 3’ end of the APC gene, particularly distal 
to codon 1399, might be associated with a greater tendency 
to development of DT, but findings are not always consistent 
[9,10,15]. This study population had a high frequency of proximal 
mutations (closer to 5’ end) on the APC gene. Only 2 patients had 
mutations within the hotspot region between codons 1250 and 
1464 [9]. This mutational pattern is not frequently reported on FAP 
patients with DT development [9].
According to Church et al., patients which have the shortest 
interval between surgery and DT appearance have the highest 
staging [8,17,18]. There seems to be such a relation on this study 
population. Patients classified as stage I have clearly the longest 
interval from surgery to DT diagnosis [Table/Fig-2]. 
The diagnosis of FAP related DT is made clinically in relation to a 
mass on the abdominal region, while investigating symptoms or 
incidentally on imaging or surgery. In this study population most 
DT were detected clinically, but four patients with intra-abdominal 
tumours were diagnosed by CT scan, during the investigation of 
ileoanal pouch dysfunction. Such presentation should prompt 
investigation and imaging is essential because DT is a possible 
aetiology, particularly in known affected families. CT is the most 
common image modality for diagnosis confirmation, identifying 
other DT and their characterization, such as determining the 
extent of invasion onto vital structures [4]. All of our patients 
underwent CT for this purpose. MRI might be useful when elective 
surgery is contemplated for an intra-abdominal DT [4]. There is 
no recommendation to actively search for DT on FAP patients, 
since they are benign and their clinical importance is related to 
symptoms. Although rare, it is possible for a DT to present itself 
as a life threatening complication, such as a GIH as reported in 
this study.
Treatment for DT may be challenging. Surgery has been advocated 
as the gold standard whenever feasible [1,3,19]. Currently, many 
authors consider medical treatment or even a wait-and-see 
approach on the management of these patients, since >50% have 
a slow growing or potentially regressive disease [5]. In fact, the 
Italian and French Sarcoma Group review, contemplate a wait-
and-see approach for most patients [5].
There are some questions when considering a low threshold 
surgical approach. First of all, DT shows a variable behaviour and 
so far there are no reliable factors that predict it. Surgery itself 
is a possible trigger of further tumorigenesis [11]. Even though 
free histologic margins seem to be a prognostic factor of local 
recurrence, there are reports that show a less clear relation [4,5,20-
number of Dt number of patients
1 5
2 4
>2 1
Staging (church
I 4
II -
III 4
IV 2
time between surgery and diagnosis Months: mean (min-max)
 All patients 60 (2-372)
stage I 279
stage II -
stage III 24
stage IV 69
[table/Fig-2]: Characterization of intra-abdominal DT at diagnosis.
Staging * treatment$ number of patients
I NSAIDs 2
Tamoxifen - surgery 1 
NSAIDs and tamoxifen –surgery 1 
II - 0
III NSAIDs 1
NSAIDs and  tamoxifen 2
NSAIDs –surgery 1
IV NSAIDs and tamoxifen - chemotherapy 1
surgery – chemotherapy – NSAIDs 1
[table/Fig-3]: Management of patients.
* initial staging $ at any point
Patient status number of patients
Dead 1 
Symptomatic 1 
Asymptomatic 15
[table/Fig-4]: Patients status. 
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22]. Recurrences might occur after complete resections. Moreover, 
patients that develop recurrence after surgery may remain stable 
without further treatment [3]. As such, negative margins should be 
achieved only if not associated with increased morbidity.
In this study there is only one abdominal wall DT resection reported. 
The margins were negative but the patient had recurrence. At that 
time the decision to perform surgery was based on the available 
literature. The evidence that most patients did not have progressive 
disease, led us to a conservative non-surgical approach for the 
remainder of patients with abdominal wall DT.
However, FAP related DT is mostly intra-abdominal [13]. The 
usual infiltrative pattern of mesenteric DT poses difficulties 
regarding surgery. The required complex surgeries, most often 
with incomplete resections, the high risk of iatrogenic injuries, the 
possibility of intestinal failure and the uncertainty of results, are 
major drawbacks to perform surgery on such patients [15,22-
24]. Surgery should be planned if complications are eminently 
expected or actually happen. 
We performed surgery only on four patients with intra-abdominal 
DT, all because of complications, most notably gastrointestinal 
haemorrhage and perforation.
There are various options for medical treatment of DT despite a 
lack of full knowledge of their mechanisms of action [25]. Currently 
there are no randomized trials comparing different options.
The most common medical treatment consists of NSAIDs. 
Indomethacin and sulindac (long-acting analogue of indomethacin), 
have been tested with variable reported responses [4,26]. 
Celecoxib, frequently prescribed for control of duodenal and colic 
adenomas, is also used for DT treatment but there is no clear 
evidence of its role on this setting [27].
There is some evidence that oestrogen stimulate growth of DT. As 
such, hormone therapy has been investigated and described as 
effective in the treatment of DT, particularly Tamoxifen [4,20,26]. 
Tested doses are as high as 120mg [26].
The combination of hormone therapy with NSAIDs is widely used 
since it is associated with low toxicity and possibly better outcome 
than isolated therapies [4]. We have used NSAIDs on most patients 
and used them associated with tamoxifen on patients who did not 
respond or did not tolerate NSAIDs. We did not use this strategy 
on 2 patients. One patient underwent emergent surgery for stage 
IV disease while the other patient had the clinical diagnosis of a 
small parietal asymptomatic DT three months ago and still awaits 
better characterization with a CT scan to evaluate the adequate 
therapy, including a possible wait and see approach.
Radiotherapy (RT) is considered a useful adjuvant therapy for DT, 
particularly when there are positive or close surgical margins. There 
are limitations to the use of RT in FAP patients, because most DT 
are located in the abdomen, and on this location, it is associated 
with serious side effects. We did not offer this treatment to any 
patient.
Imatinib has been studied, as well as other tyrosine kinase inhibitors. 
So far results vary between stabilization and 15% response rates. 
Its use is only justifiable in a trial setting [4,25].
Interferon has been scarcely reported as an optionand currently is 
not recommended [4,26].
Cytotoxic chemotherapy is reserved for patients with aggressive 
disease, who don’t respond to less toxic treatment and when DT 
are not amenable to resection. The major concern is its use for 
a benign disease on a generally young population, and its late 
side effects. The French Sarcoma Group has reviewed the effect 
of chemotherapy in patients with DT and concluded there is a 
clear benefit, particularly with anthracyclines, despite side effects 
[28]. Our regimen consisted, on both patients, of doxorubicin and 
dacarbazine which is a common protocol on this setting [28]. Other 
common protocol is methotrexate and vinblastine/vinorelbine, 
considered safer in terms of toxicity profile [5,28]. There are no 
follow-up recommendations on these patients in the literature.
cOnclusIOn
Diagnosis of DT in PAF patients is based on clinical symptoms, 
without the need for screening, although imaging plays an 
important role once diagnosis is suspected. The treatment 
approach is conservative on most patients, mainly with NSAIDs 
and tamoxifen, leaving surgery for DT related complications. Most 
patients follow an indolent path. The follow-up of patients with DT 
is also based on clinical symptoms.
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